Glioblastoma

Why trials studying Glioblastoma stopped, in this sample of ClinicalTrials.gov.

22 stopped trials with a clear reason; 82% ended for non-scientific reasons.

Trials

• Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas
  NCT06455189 · WITHDRAWN · regulatory
  “Terminated IRB”
• Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
  NCT06038760 · TERMINATED · funding business
  “Lack of funding”
• Monocyte Antigen Carrier Cells for Newly Diagnosed GBM
  NCT04741984 · WITHDRAWN · funding business
  “Due to need to proceed with procedural changes with goals of improving the technical and economic feasibility.”
• GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM
  NCT05695976 · SUSPENDED · other
  “The study is suspended while preplanned interim analysis is being completed.”
• Predicting Response Patterns to Treatment in Glioblastoma (GBM) Patients
  NCT04219475 · SUSPENDED · funding business
  “Priority changes of the company”
• A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
  NCT04200066 · WITHDRAWN · funding business
  “One of the drugs for the study is not commercially available.”
• Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
  NCT05267106 · TERMINATED · futility
  “Recruitment ceased after a pre-planned futility interim analysis indicated a low probability to confer a clinically meaningful improvement in objective response when compared to currently available therapies. There were no safety related concerns.”
• Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab
  NCT04681677 · TERMINATED · funding business
  “unspecified business decision”
• Neoadjuvant Chemoradiation for Resectable Glioblastoma
  NCT04209790 · TERMINATED · logistics pi
  “Suspended to identify a permanent PI at site level. Decision to Terminate was made on 7/29/25 because no other PI able to take on project.”
• 18F-FluorThanatrace (PET/CT) in Glioblastoma
  NCT04221061 · TERMINATED · futility
  “Companion treatment trial closed early with negative results. No imaging study participants completed the full study imaging planned due to logistical difficulties.”
• Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
  NCT04006119 · TERMINATED · funding business
  “Sponsor Decision”
• Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma
  NCT03506139 · WITHDRAWN · funding business
  “Not funded”
• Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
  NCT03707457 · TERMINATED · funding business
  “Funding/material support withdrawn”
• Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
  NCT02743078 · TERMINATED · funding business
  “Treatment now available commercially”
• A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
  NCT02754362 · WITHDRAWN · logistics pi
  “Due to personnel changes / departure of Dr. Chi.”
• Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma
  NCT02876003 · WITHDRAWN · other
  “This study has been withdrawn prior to enrollment.”
• Discerning Pseudoprogression vs True Tumor Growth in GBMs
  NCT02905643 · TERMINATED · logistics pi
  “Investigator left institution”
• Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma
  NCT02254954 · TERMINATED · slow accrual
  “Sponsor decision due to low recruitment”
• Stress, Exercise Behavior and Survival in Patients With Newly Diagnosed Glioblastoma and in a Close Partner
  NCT02129335 · TERMINATED · slow accrual
  “insufficient enrollment”
• Derivation of Tumor Specific Hybridomas
  NCT01702792 · TERMINATED · logistics pi
  “Investigator is leaving Dartmouth”
• Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma
  NCT02841332 · TERMINATED · slow accrual
  “lack of recruitment”
• Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
  NCT00761280 · TERMINATED · slow accrual
  “Unable to recruit the projected patient number. All analyses are descriptive, only.”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.